Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma

Background Due to the poor prognosis for advanced renal cell carcinoma (RCC), there is an urgent need for new therapeutic targets and for prognostic markers to identify high risk tumors. MicroRNAs (miRNAs) are frequently dysregulated in tumors, play a crucial role during carcinogenesis and therefore might be promising new biomarkers. In previous studies, we identified miR-141-3p and miR-145-5p to be downregulated in clear cell RCC (ccRCC). Our objective was to investigate the functional association of these miRNAs, focusing on the cooperative regulation of new specific targets and their role in ccRCC progression. Methods The effect of miR-141-3p and miR-145-5p on cell migration was examined by overexpression in 786-O cells. New targets of both miRNAs were identified by miRWalk, validated in 786-O and ACHN cells and additionally characterized in ccRCC tissue on mRNA and protein level. Results In functional analysis, a tumor suppressive effect of miR-141-3p and miR-145-5p by decreasing migration and invasion of RCC cells could be shown. Furthermore, co-overexpression of the miRNAs seemed to result in an increased inhibition of cell migration. Both miRNAs were recognized as post-transcriptional regulators of the targets EAPP, HS6ST2, LOX, TGFB2 and VRK2. Additionally, they showed a cooperative effect again as demonstrated by a significantly increased inhibition of HS6ST2 and LOX expression after simultaneous overexpression of both miRNAs. In ccRCC tissue, LOX mRNA expression was strongly increased compared to normal tissue, allowing also to distinguish between non-metastatic and already metastasized primary tumors. Finally, in subsequent tissue microarray analysis LOX protein expression showed a prognostic relevance for the overall survival of ccRCC patients. Conclusion These results illustrate a jointly strengthening effect of the dysregulated miR-141-3p and miR-145-5p in various tumor associated processes. Focusing on the cooperative effect of miRNAs provides new opportunities for the development of therapeutic strategies and offers novel prognostic and diagnostic capabilities.

[1]  Klaus Jung,et al.  Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p , 2016, PloS one.

[2]  F. Kabbinavar,et al.  Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. , 2015, Critical reviews in oncology/hematology.

[3]  I. Ng,et al.  MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility , 2015, Frontiers of Medicine.

[4]  R. Linding,et al.  The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase , 2015, Nature.

[5]  K. Tang,et al.  Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis , 2015, Scientific Reports.

[6]  Wei Liu,et al.  Expression and clinical significance of the microRNA-200 family in gastric cancer. , 2015, Oncology letters.

[7]  Nao Nishimura,et al.  Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1 , 2015, Experimental Hematology & Oncology.

[8]  Yan-bin Zhang,et al.  miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1) , 2015, Oncotarget.

[9]  S. Marie,et al.  LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation , 2015, PloS one.

[10]  W. Rathmell,et al.  Renal cell carcinoma , 2014, BMJ : British Medical Journal.

[11]  H. Verheul,et al.  Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. , 2014, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  J. Erler,et al.  Lysyl oxidase in cancer research. , 2014, Future oncology.

[13]  A. Navarro,et al.  miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma , 2014, PloS one.

[14]  A. Gadducci,et al.  Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[15]  Xing-Sui Lu,et al.  miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression , 2014, Clinical Cancer Research.

[16]  C. Deltas,et al.  New miRNA Profiles Accurately Distinguish Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas from the Normal Kidney , 2014, PloS one.

[17]  R. Dahiya,et al.  Long Non-coding RNA HOTAIR Is Targeted and Regulated by miR-141 in Human Cancer Cells* , 2014, The Journal of Biological Chemistry.

[18]  Zhi-mao Jiang,et al.  miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.

[19]  N. Seki,et al.  Tumor‐suppressive microRNA‐143/145 cluster targets hexokinase‐2 in renal cell carcinoma , 2013, Cancer science.

[20]  W. Weichert,et al.  Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis , 2013, Journal of Translational Medicine.

[21]  L. Antunes,et al.  MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis , 2013, British Journal of Cancer.

[22]  H. Mollenkopf,et al.  miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. , 2013, The Journal of molecular diagnostics : JMD.

[23]  K. Okuno,et al.  Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer , 2013, Molecular and clinical oncology.

[24]  Luke H. Hoeppner,et al.  Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin. , 2013, Cancer research.

[25]  Ioannis S Vlachos,et al.  Online resources for miRNA analysis. , 2013, Clinical biochemistry.

[26]  A. Ekici,et al.  MicroRNA profiles classify papillary renal cell carcinoma subtypes , 2013, British Journal of Cancer.

[27]  D. Lindgren,et al.  Effects of TGF-β signaling in clear cell renal cell carcinoma cells. , 2013, Biochemical and biophysical research communications.

[28]  N. Seki,et al.  Epithelial–mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma , 2013, Journal of Human Genetics.

[29]  M. V. van Dijk,et al.  The entire miR‐200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney , 2013, Genes, chromosomes & cancer.

[30]  R. Blaheta,et al.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. , 2013, Neoplasia.

[31]  P. Lazo,et al.  Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression , 2013, Cell Death and Disease.

[32]  J. Erler,et al.  Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. , 2013, Cancer research.

[33]  Yong Ho Bae,et al.  Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. , 2012, Cell reports.

[34]  K. Schaser,et al.  Identification of Metastamirs as Metastasis-associated MicroRNAs in Clear Cell Renal Cell Carcinomas , 2012, International journal of biological sciences.

[35]  S. Stringer,et al.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes , 2012, Virchows Archiv.

[36]  Thomas R. Cox,et al.  The rationale for targeting the LOX family in cancer , 2012, Nature Reviews Cancer.

[37]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[38]  F. Watt,et al.  FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. , 2012, Cancer research.

[39]  A. Poprach,et al.  Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients , 2012, Genes, chromosomes & cancer.

[40]  A. Disch,et al.  Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. , 2011, Analytical biochemistry.

[41]  J. Patard,et al.  ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. , 2011, European urology.

[42]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[43]  C. Stephan,et al.  MicroRNAs as regulators of signal transduction in urological tumors. , 2011, Clinical chemistry.

[44]  Qin Li,et al.  Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. , 2011, The Biochemical journal.

[45]  Guido Jenster,et al.  Androgen regulation of micro‐RNAs in prostate cancer , 2011, The Prostate.

[46]  Jing Chen,et al.  MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing , 2011, PloS one.

[47]  Masayuki Kano,et al.  miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma , 2010, International journal of cancer.

[48]  A. Rustgi,et al.  The role of the miR-200 family in epithelial-mesenchymal transition , 2010, Cancer biology & therapy.

[49]  C. Stephan,et al.  Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. , 2010, Clinical chemistry.

[50]  K. D. Sørensen,et al.  miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors , 2010, Oncogene.

[51]  K. Eckardt,et al.  The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia , 2009, The Journal of Biological Chemistry.

[52]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[53]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[54]  M. Seto,et al.  Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.

[55]  K. Kimura,et al.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. , 2007, The Journal of clinical investigation.

[56]  M. Hendrix,et al.  Paradoxical roles for lysyl oxidases in cancer—A prospect , 2007, Journal of cellular biochemistry.

[57]  G. Kristiansen,et al.  In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR , 2007, BMC Molecular Biology.

[58]  K. Csiszȧr,et al.  Intracellular localization of the matrix enzyme lysyl oxidase in polarized epithelial cells. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[59]  H. Kagan,et al.  Lysyl oxidase: an oxidative enzyme and effector of cell function , 2006, Cellular and Molecular Life Sciences CMLS.

[60]  M. Hendrix,et al.  Lysyl oxidase regulates actin filament formation through the p130Cas/Crk/DOCK180 signaling complex , 2006, Journal of cellular biochemistry.

[61]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[62]  M. Hendrix,et al.  Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. , 2005, Cancer research.

[63]  A. Kaneda,et al.  Lysyl Oxidase Is a Tumor Suppressor Gene Inactivated by Methylation and Loss of Heterozygosity in Human Gastric Cancers , 2004, Cancer Research.

[64]  S. Mian,et al.  Anti-tumour therapeutic efficacy of OX40L in murine tumour model. , 2004, Vaccine.

[65]  R. Oleggini,et al.  Demonstration of in vitro interaction between tumor suppressor lysyl oxidase and histones H1 and H2: definition of the regions involved. , 2003, Biochimica et biophysica acta.

[66]  H. Kagan,et al.  Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell , 2003, Journal of cellular biochemistry.

[67]  M. Hendrix,et al.  A molecular role for lysyl oxidase in breast cancer invasion. , 2002, Cancer research.

[68]  C. Compton,et al.  TNM residual tumor classification revisited , 2002, Cancer.

[69]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  F. Marshall,et al.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. , 2001, The American journal of pathology.

[71]  H. Kagan,et al.  Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth‐muscle cells , 2000, Journal of cellular biochemistry.

[72]  M. Mello,et al.  Modulation of ras transformation affecting chromatin supraorganization as assessed by image analysis. , 1995, Experimental cell research.

[73]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[74]  Ju-Han Lee,et al.  Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. , 2015, Human pathology.

[75]  K. Jung,et al.  MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. , 2013, Critical reviews in oncogenesis.

[76]  Vascular Access , 2006 .

[77]  Guanmei Liu,et al.  Lysyl oxidase oxidizes basic fibroblast growth factor and inactivates its mitogenic potential , 2003, Journal of cellular biochemistry.

[78]  H. Rotheneder,et al.  @ Address correspondence to: , 2022 .